Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer

Prostate

Volumn 39, Issue 2, 1999, Pages 79-86

  Sattler, Hans Peter ^a   Rohde, Volker ^a   Bonkhoff, Helmut ^a   Zwergel, Thomas ^a   Wullich, Bernd ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Chromosome; Gene amplification; Prostate tumor; Tumor cytogenetics

Indexed keywords

ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME IDENTIFICATION; CHROMOSOME LOSS; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DNA SEQUENCE; GENE AMPLIFICATION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMAGE ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTO ONCOGENE;

ADENOCARCINOMA; DNA, NEOPLASM; HUMANS; MALE; MUTATION; NUCLEIC ACID HYBRIDIZATION; PROSTATIC NEOPLASMS;

EID: 0033119966     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990501)39:2<79::AID-PROS1>3.0.CO;2-2     Document Type: Article

References (51)

1. Lundgren R, Mandahl N, Heim S, Limon J, Henrikson H, Mitelman F. Cytogenetic analysis of 57 primary prostatic adenocarcinomas. Genes Chromosomes Cancer 1992;4:16-24.
2. Breitkreuz T, Romanakis K, Lutz S, Seitz G, Bonkhoff H, Unteregger G, Zwergel T, Zang KD, Wullich B. Genotypic characterization of prostatic carcinomas: a combined cytogenetic, flow cytometry, and in situ DNA hybridization study. Cancer Res 1993;53:4035-4040.
3. Barreton GB, Valina C, Vogt T, Schneiderbanger K, Diebold J, Löhrs U. Interphase cytogenetic analysis of prostatic carcinomas by use of nonisotopic in situ hybridization. Cancer Res 1994;54: 4472-4480.
4. Brothman AR, Watson MJ, Zhu KL, Williams BJ, Rohr LR. Evaluation of 20 archival prostate tumor specimens by fluorescence in situ hybridization (FISH). Cancer Genet Cytogenet 1994;75:40-44.
5. Brown JA, Alcaraz A, Takahashi S, Persons DL, Lieber MM, Jenkins RB. Chromosomal aneusomies detected by fluorescent in situ hybridization analysis in clinically localized prostate carcinoma. J Urol 1994;152:1157-1162.
6. Visakorpi T, Hyytinen E, Kallioniemi A, Isola J, Kallioniemi OP. Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am J Pathol 1994;145:624-630.
7. Ketter R, Zwergel T, Romanakis K, Unteregger G, Ziegler M, Zang KD, Wullich B. Selection toward diploid cells in prostatic carcinoma derived cell cultures. Prostate 1996;28:364-371.
8. Micale MA, Sanford JS, Powell IJ, Sakr WA, Wolman SR. Defining the extent and nature of cytogenetic events in prostatic adenocarcinoma: paraffin FISH vs. metaphase analysis. Cancer Genet Cytogenet 1993;69:7-12.
9. Steilen S, Ketter R, Romanakis K, Zwergel T, Unteregger G, Bonkhoff H, Seitz G, Ziegler M, Zang KD, Wullich B. DNA aneuploidy in prostatic adenocarcinoma: a frequent event as shown by fluorescence in situ hybridization. Hum Pathol 1994; 25:1306-1313.
10. Alcaraz A, Takahashi S, Brown JA, Herath JF, Bergstralh EJ, Larson KJ, Lieber MM, Jenkins RB. Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are marker of poor prognosis in prostate cancer. Cancer Res 1994;54:3998-4002.
11. Bandyk MG, Zhao L, Troncoso P, Pisters LL, Palmer JL, Eschenbach von AC, Chung LWK, Liang JC. Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 1994;9:19-27.
12. Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI, Isaacs WB. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA 1990;87:8751-8755.
13. Kunimi K, Bergerheim US, Larsson IL, Ekman P, Collins VP. Allelotyping of human prostatic adenocarcinoma. Genomics 1991;11:530-536.
14. Gao X, Honn KV, Grignon D, Sakr W, Chen YQ. Frequent loss of expression and loss of heterozygosity of the putative tumor suppressor gene DCC in prostate cancer. Cancer Res 1993;53: 2723-2727.
15. Latil A, Baron JC, Cussenot O, Fournier G, Soussi T, Boccon GL, Le DA, Rouesse J, Lidereau R. Genetic alterations in localized prostate cancer. Identification of a common region of deletion on chromosome arm 18q. Genes Chromosomes Cancer 1994;11: 119-125.
16. Phillips SM, Morton DG, Lee SJ, Wallace DM, Neoptolemos JP. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br J Urol 1994;73:390-395.
17. Sakr WA, Macoska JA, Benson P, Grignon DJ, Wolman SR, Pontes JE, Crissman JD. Allelic loss in locally metastatic, multi-sampled prostate cancer. Cancer Res 1994;54:3273-3277.
18. Cher ML, Ito T, Weidner N, Carroll PR, Jensen RH. Mapping of regions of physical deletion on chromosome 16q in prostate cancer cells by fluorescence in situ hybridization (FISH). J Urol 1995;153:249-254.
19. Ueda T, Komiya A, Emi M, Suzuki H, Shiraishi T, Yatani R, Masai M, Yasuda K, Ito H. Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 1997;20:140-147.
20. Bova GS, Carter BS, Bussemakers MJ, Emi M, Fujiwara Y, Kyprianou N, Jacobs SC, Robinson JC, Epstein JI, Walsh PC, Isaacs WB. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 1993;53: 3869-3873.
21. MacGrogan D, Levy A, Bostwick D, Wagner M, Wells D, Bookstein R. Loss of chromosome 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer 1994;10:151-159.
22. Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim USR. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 1994;9:3071-3076.
23. Trapman J, Sleddens HF, van der Weiden MM, Dinjens WN, König JJ, Schröder FH, Faber PW, Bosman FT. Loss of heterozygosity of chromosome 8 microsatellite loci implicates a candidate tumor suppressor gene between the loci D8S87 and D8S133 in human prostate cancer. Cancer Res 1994;54:6061-6064.
24. Suzuki H, Emi M, Komiya A, Fujiwara Y, Yatani R, Nakamura Y, Shimazaki J. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 mb region of 8p22-p21.3. Genes Chromosomes Cancer 1995;13: 168-174.
25. Kallioniemi A, Kallioniemi OP, Sudar D, Rutovitz D, Gray JW, Waldman F, Pinkel D. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 1992; 258:818-821.
26. Schroeder FH, Hermanek P, Denis L. The TNM classification of prostate carcinoma. Prostate [Suppl] 1992;4:129-138.
27. Mostofi FK, Sesterhenn IA, Sobin LH, editors. Histological typing of prostate tumours. In: International histological classification of tumours no. 22. Geneva: World Health Organization; 1980.
28. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, Pinkel D. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994;10:231-243.
29. Joos S, Bergerheim USR, Pan Y, Matsuyama H, Bentz M, Manoir du S, Lichter P. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 1995;14:267-276.
30. Visakorpi T, Kallioniemi AH, Syvänen AC, Hyytinen ER, Karhu R, Tammela T, Isola JJ, Kallioniemi OP. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res 1995;55:342-347.
31. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 1996;56:3091-3102.
32. Williams BJ, Jones E, Kozlowski JM, Vessella R, Brothman AR. Comparative genomic hybridization and molecular cytogenetic characterization of two prostate cancer xenografts. Genes Chromosomes Cancer 1997;18:299-304.
33. Nupponen NN, Hyytinen ER, Kallioniemi AH, Visakorpi T. Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genet Cytogenet 1998; 101:53-57.
34. Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, Pedersen-Bjergaard J, Parganas E, Ihle JN, Rowley JD. Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci USA 1994;91: 4004-4008.
35. Yoneda-Kato N, Look AT, Kirstein MN, Valentine MB, Raimondi SC, Cohen KJ, Carroll AJ, Morris SW. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996;12:265-275.
36. Takai S, Long JE, Yamada K, Miki T. Chromosomal localization of the human ECT2 proto-oncogene to 3q26.1q26.2 by somatic cell analysis and fluorescence in situ hybridization. Genomics 1995;27:220-222.
37. Soder AI, Hoare SF, Muir S, Going JJ, Parkinson EK, Keith WN. Amplification, increased dosage and in situ expression of the telomerase RNA gene in human cancer. Oncogene 1997;14: 1013-1021.
38. Arheden K. Amplification of the human putative oncogene INT1 in primary retinoblastoma tumors. Cytogenet Cell Genet 1988;48:174-177.
39. Khatib ZA, Matsushime H, Valentine M, Shapiro DN, Sherr CJ, Look AT. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993;53:5535-5541.
40. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PM, Collins VP. Amplification of multiple genes from chromosome region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS and MDM2. Cancer Res 1994;54:4299-4303.
41. Flemming WH, Hamel A, MacDonald R, Ramsey E, Pettigrew NM, Johnston B, Dodd JG, Matusik RJ. Expression of the c-myc proto-oncogene in human prostatic carcinoma and benign hyperplasia. Cancer Res 1986;46:1535-1538.
42. Buttyan R, Sawczuk IS, Benson MC, Siegal JD, Olsson CA. Enhanced expression of the c-myc proto-oncogene in high-grade human prostate cancers. Prostate 1987;11:327-337.
43. Brown CJ, Goss SJ, Lubahn DB, Joseph DR, Wilson EM, French FS, Willard HF. Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 1989;44:264-269.
44. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinänen R, Palmberg C, Palotie A, Tammela T, Isola J, Kallioniemi OP. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995;9:401-406.
45. Marchio A, Meddeb M, Pineau P, Danglot G, Tiollais P, Bernheim A, Dejean A. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
46. Lastowska M, Nacheva E, McGuckin A, Curtis A, Grace C, Pearson A, Bown N. Comparative genomic hybridization study of primary neuroblastoma tumors. Genes Chromosomes Cancer 1997;18:162-169.
47. Bièche I, Champème MH, Matifas F, Cropp CS, Callahan R, Lidereau R. Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res 1993;53:1990-1994.
48. Mathew S, Murty WS, Bosl GJ, Chaganti RSK. Loss of heterozygosity identifies multiple sites of allelic deletions on chromosome 1 in human male germ cell tumors. Cancer Res 1994;54: 6265-6269.
49. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993;53: 4349-4355.
50. Martinsson T, Sjöberg RM, Hedborg F, Kogner P. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short term-tandem repeat polymorphisms. Cancer Res 1995;55:5681-5686.
51. Bentz M, Plesch A, Stilgenbauer S, Döhner H, Lichter P. Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 1998;21:172-175.